

# Contents

Business and Management	Value Creation	Foundation for Value Creation	Value Preservation	Strengthening of Corporate Governance	Financial Information
 P5	 P25	 P39	 P61	 P83	 P100
<b>Advances in Challenges Taken On</b> ..... 5 <b>Business and Features</b> ..... 7 <b>Financial &amp; Non-Financial Highlights</b> ..... 9 <b>Top Message</b> ..... 11 <b>ONO's Value Creation Process</b> ..... 17 <b>Sustainable Management Policy</b> ... 19 <b>Growth Strategy</b> ..... 21 <b>Redefinition of Material Issues</b> ..... 23	<b>Creation of Innovative Drugs</b> ..... 27 <b>Pipeline Expansion</b> ..... 29 <b>Maximization of Product Value</b> .... 33 <b>Realization of Direct Sales in the US and Europe</b> ..... 35 <b>Expansion of Business Domains</b> ... 37	<b>Corporate Transformation through Digital &amp; IT</b> ..... 41 <b>Strengthening of Financial Capital</b> ..... 43 <b>Expansion of Human Capital</b> ..... 47 <b>Intellectual Property Strategies</b> ... 55 <b>Open Innovation</b> ..... 57 <b>Promotion of Diverse Partnerships</b> ..... 59	<b>Assurance of Product Reliability and Safety</b> ..... 63 <b>Stable Supply of Products</b> ..... 64 <b>Protection of Environment</b> ..... 65 <b>Respect for Human Rights</b> ..... 72 <b>Thorough Compliance</b> ..... 77 <b>Supply Chain Management</b> ..... 80 <b>Social Contribution Activities</b> ..... 81	<b>Round-table Discussion with the Outside Directors</b> ..... 85 <b>Management</b> ..... 89 <b>Corporate Governance</b> ..... 91 <b>Risk Management</b> ..... 98	<b>Financial Review</b> ..... 101 <b>Consolidated Financial Summary</b> ..... 103 <b>Details of Revenue</b> ..... 105 <b>Consolidated Financial Statement</b> ..... 106 <b>Corporate Information / Stock Information</b> ..... 110

## Editorial Policy

In this report, ONO Pharmaceutical (ONO) reports on the Group's efforts to create value in line with the material issues we have newly identified as important management issues. We introduce key financial and non-financial initiatives centered on the value we should provide as a pharmaceutical company to achieve sustainable growth for the company and society. We publish this report as a communication tool to help stakeholders understand our current status and direction.

### Coverage of this Report

- **Scope of Coverage:** This report covers the activities of ONO. Some pages also include the activities of the whole Group or group companies.
- **Period of Coverage:** April 1, 2021 through March 31, 2022
- \* The report is based on activities in FY2021, the period for the financial reports, however, considering the importance of providing the most up-to-date information, some activities conducted in and after April 2022 are also covered.

### Reference Guidelines

ONO refers to the International Integrated Reporting Framework issued by the International Integrated Reporting Council (IIRC), Guidance for Integrated Corporate Disclosure and Company-Investor Dialogue for Collaborative Value Creation compiled by the Ministry of Economy, Trade and Industry of Japan, Environmental Reporting Guidelines 2018 by the Ministry of the Environment of Japan, and the Final Report on Recommendations of the Task Force on Climate-related Financial Disclosures (TCFD). The GRI Standards are also referred to. Comparative tables are on the Sustainability pages of our website. <https://sustainability.ono-pharma.com/en>

**Publication Date:**  
September 2022

### Disclaimer Regarding Forward-Looking Statements

This report includes forward-looking statements regarding the ONO Group's business. All the forward-looking statements are based on forecast analysis using the information available at the time of preparation of this report. Actual financial results may therefore differ from the current business outlook due to market and industry conditions, and risks and uncertainties associated with general economic conditions at home and abroad. This report also includes information that provides details of pharmaceutical products, including compounds under development. Please note, however, that this information is not intended for advertising purposes or for giving medical advice.

### Related Information

Corporate site  
<https://www.ono-pharma.com/>  
Information on ONO's Sustainability Initiatives  
<https://sustainability.ono-pharma.com/en>  
Financial Report  
[https://www.ono-pharma.com/ir/library/financial\\_results.html](https://www.ono-pharma.com/ir/library/financial_results.html)  
Corporate Governance Report  
[https://www.ono-pharma.com/sites/default/files/en/ir/corporate\\_governance\\_report\\_en.pdf](https://www.ono-pharma.com/sites/default/files/en/ir/corporate_governance_report_en.pdf)

## External ESG Assessment of ONO PHARMACEUTICAL

### ONO included in premier indices for socially responsible investment (SRI)

<p>Member of <b>Dow Jones Sustainability Indices</b> Powered by the S&amp;P Global CSA</p> <p><b>Dow Jones Sustainability Indices (DJSI)</b> Jointly developed by S&amp;P Dow Jones Indices (US) and RobecoSAM (Switzerland) to evaluate companies based on an analysis of those companies' economic, environmental and social performance</p>	<p><b>2021 CONSTITUENT MSCI JAPAN ESG SELECT LEADERS INDEX</b></p> <p><b>MSCI Japan ESG Select Leaders Index</b> Designed to target companies that have relatively high ESG performance</p>	<p><b>Recognition of ONO's environmental performance</b></p> <p> <b>CDP2021 [Climate Change] [Water Security] A List</b></p> <p>Global accreditation by international environmental NGO CDP to name the world's top-rate businesses leading on environmental performance in climate change and water security</p>
<p> <b>FTSE4Good</b></p> <p><b>FTSE4Good Index Series</b> Created by FTSE Russell to measure the performance of companies demonstrating strong ESG practices</p>	<p> <b>FTSE Blossom Japan</b></p> <p><b>FTSE Blossom Japan Index</b> Created by FTSE Russell, designed as an industry neutral benchmark that reflects the performance of Japanese companies demonstrating strong ESG practices</p>	<p><b>Recognition of ONO's safety &amp; health performance</b></p> <p> <b>2022 Certified Health &amp; Productivity Management Outstanding Organization Recognition Program "White 500"</b></p> <p>ONO has been recognized as a company engaging in strategic health and productivity management program efforts for maintaining its employees' health from a management perspective</p>

**DISCLAIMER:** THE INCLUSION OF ONO PHARMACEUTICAL CO., LTD. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF ONO PHARMACEUTICAL CO., LTD. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.